SYNEOS HEALTH, INC.

(SYNH)
  Report
Delayed Nasdaq  -  05/27 04:00:01 pm EDT
75.18 USD   +4.53%
05/25Cabral Gold to Raise up to $5 Million in Public Offering of Units
MT
05/24Syneos Health to Present at Upcoming Investor Conferences
AQ
05/24Guggenheim Starts Syneos Health at Buy With $81 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SYNEOS HEALTH, INC. : Change in Directors or Principal Officers (form 8-K)

01/18/2022 | 06:37am EDT

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 14, 2022, the Board of Directors (the "Board") of Syneos Health, Inc. (the "Company") appointed Barbara W. Bodem and Alfonso G. Zulueta to the Board, in each case effective January 15, 2022. Ms. Bodem was appointed to serve as a Class I director of the Company with an initial term expiring on the date of the Company's 2024 annual meeting of stockholders and to serve on the Audit Committee of the Board. Mr. Zulueta was appointed to serve as a Class III director of the Company with an initial term expiring on the date of the Company's 2023 annual meeting of stockholders.

The Board reviewed and discussed the qualifications of Ms. Bodem and Mr. Zulueta as director nominees and determined that each of them is an "independent director" in accordance with the Nasdaq listing standards, including those pertaining to service on an audit committee with respect to Ms. Bodem.

Ms. Bodem and Mr. Zulueta will be compensated for their service as directors in the same manner as the Company's other non-employee directors. They will each receive an annual cash retainer of $95,000 for their Board service and Ms. Bodem will receive a cash retainer of $12,000 for her service on the Audit Committee, each of which will be prorated for the effective date of their appointment. In addition, in connection with their appointment to the Board, Ms. Bodem and Mr. Zulueta each received an equity award in an amount consistent with the awards granted annually to non-employee directors that have a grant date fair value of $200,000, which was prorated for the effective date of their appointment, and which vests in full one year from the grant date, subject to his or her service through the applicable vesting date.

Neither Ms. Bodem nor Mr. Zulueta is a party to any transaction requiring disclosure pursuant to Item 404(a) of Regulation S­K. Ms. Bodem and Mr. Zulueta each entered into the Company's standard form of director Indemnification Agreement.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about SYNEOS HEALTH, INC.
05/25Cabral Gold to Raise up to $5 Million in Public Offering of Units
MT
05/24Syneos Health to Present at Upcoming Investor Conferences
AQ
05/24Guggenheim Starts Syneos Health at Buy With $81 Price Target
MT
05/10Syneos Health Leaders Recognized by HBA
AQ
05/02Syneos Health Names Michelle Keefe as Next Chief Executive Officer
AQ
05/02Syneos Health Reports First Quarter 2022 Results
AQ
04/29SYNEOS HEALTH, INC. : Change in Directors or Principal Officers, Financial Statements and ..
AQ
04/29SYNEOS HEALTH : Q1 2022 Financial Results Presentation
PU
04/29Syneos Health Promotes Michelle Keefe to CEO, Michael Brooks to COO
MT
04/29Syneos Health's Q1 Adjusted Earnings, Revenue Increase; Boosts FY22 EPS Guidance
MT
More news
Analyst Recommendations on SYNEOS HEALTH, INC.
More recommendations
Financials (USD)
Sales 2022 5 669 M - -
Net income 2022 297 M - -
Net Debt 2022 2 684 M - -
P/E ratio 2022 26,3x
Yield 2022 -
Capitalization 7 712 M 7 712 M -
EV / Sales 2022 1,83x
EV / Sales 2023 1,63x
Nbr of Employees 26 751
Free-Float 59,7%
Chart SYNEOS HEALTH, INC.
Duration : Period :
Syneos Health, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SYNEOS HEALTH, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 75,18 $
Average target price 91,55 $
Spread / Average Target 21,8%
EPS Revisions
Managers and Directors
Michelle Keefe Chief Executive Officer & Director
Jason Michael Meggs Chief Financial Officer
John M. Dineen Chairman
Larry A Pickett Chief Information & Digital Officer
Baba Shetty President-Technology & Data Solutions
Sector and Competitors
1st jan.Capi. (M$)
SYNEOS HEALTH, INC.-26.78%7 712
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478